Dr. Herlihy joined Great Point Partners’ CEO Advisory Board in 2016.
Previously, Dr. Herlihy served as CEO and President of Repligen from 1996 to 2015. Under his leadership, Repligen grew from a market capitalization of approximately $20 million to in excess of $1 billion and became one of the leading bioprocessing companies in the United States. Repligen was one of the earliest investments made by BMVF.
Dr. Herlihy holds an A.B. degree in Chemistry from Cornell University and also a Ph.D. in Chemistry from M.I.T.
- Repligen – purification products for biologics